Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRODIGE 108 - COHORTE 2320 - COFRUQ Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer

NCT07124858 is registered in ClinicalTrials.gov with Federation Francophone de Cancerologie Digestive as lead sponsor.

NCT NCT07124858
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07124858 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRODIGE 108 - COHORTE 2320 - COFRUQ Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer
Lead sponsor
Federation Francophone de Cancerologie Digestive
Phase
Not applicable
Overall status
Recruiting
Start date
March 10, 2026
Completion date
December 31, 2031
Enrollment
300 (estimated)
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

antineoplastic agents, immunological, metastatic colorectal cancer (crc), vegfr-tki